home > drugs a-z list > carac (fluorouracil) drug center > carac (fluorouracil) drug - overdosage and contraindications

Recommended Topic Related To:

Carac

Psoriasis facts

  • Psoriasis is a chronic inflammatory skin disease.
  • Psoriasis has no known cause.
  • The tendency toward developing psoriasis is inherited in genes.
  • Psoriasis is not contagious.
  • Psoriasis gets better and worse spontaneously and can have periodic remissions (clear skin).
  • Psoriasis is controllable with medication.
  • Psoriasis is currently not curable.
  • There are many promising therapies, including newer biologic drugs.
  • Future research for psoriasis is promising.

What is psoriasis?

Psoriasis is a noncontagious skin condition that produces red, dry plaques of thickened skin. The dry flakes and skin scales are thought to result from the rapid proliferation of skin cells that is triggered by abnormal lymphocytes from the blood . Psoriasis commonly affects the skin of the elbows, knees, and scalp.

Some people have such mild ps...

Carac

font size

OVERDOSE

Ordinarily, topical overdosage will not cause acute problems. If Carac (fluorouracil) is accidentally ingested, induce emesis and gastric lavage. Administer symptomatic and supportive care as needed. If contact is made with the eye, flush with copious amounts of water.

CONTRAINDICATIONS

Fluorouracil may cause fetal harm when administered to a pregnant woman. Fluorouracil is contraindicated in women who are or may become pregnant. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.

No adequate and well-controlled studies have been conducted in pregnant women with either topical or parenteral forms of fluorouracil. One birth defect (ventricular septal defect) and cases of miscarriage have been reported when fluorouracil was applied to mucous membrane areas. Multiple birth defects have been reported in the fetus of a patient treated with intravenous fluorouracil.

Animal reproduction studies have not been conducted with Carac. Fluorouracil, the active ingredient, has been shown to be teratogenic in mice, rats, and hamsters when administered parenterally at doses greater than or equal to 10, 15 and 33 mg/kg/day, respectively, [4X, 11X and 20X, respectively, the Maximum Recommended Human Dose (MRHD) based on body surface area (BSA)]. Fluorouracil was administered during the period of organogenesis for each species. Embryolethal effects occurred in monkeys at parenteral doses greater than 40 mg/kg/day (65X the MRHD based on BSA) administered during the period of organogenesis.

Carac (fluorouracil) should not be used in patients with dihydropyrimidine dehydrogenase (DPD) enzyme deficiency. A large percentage of fluorouracil is catabolized by the enzyme dihydropyrimidine dehydrogenase (DPD). DPD enzyme deficiency can result in shunting of fluorouracil to the anabolic pathway, leading to cytotoxic activity and potential toxicities.

Carac (fluorouracil) is contraindicated in patients with known hypersensitivity to any of its components.

Last reviewed on RxList: 11/10/2008
This monograph has been modified to include the generic and brand name in many instances.

Carac - User Reviews

Carac User Reviews

Now you can gain knowledge and insight about a drug treatment with Patient Discussions.

Here is a collection of user reviews for the medication Carac sorted by most helpful. Patient Discussions FAQs

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Women's Health

Find out what women really need.